<DOC>
	<DOCNO>NCT02163057</DOCNO>
	<brief_summary>This Phase I/IIa , open-label study evaluate safety , tolerability , immunogenicity INO-3112 DNA vaccine deliver Electroporation subject HPV associate head neck squamous cell cancer .</brief_summary>
	<brief_title>Study HPV Specific Immunotherapy Patients With HPV Associated Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description>This Phase I/IIa , open-label , study evaluate safety , tolerability , immunogenicity INO-3112 [ 6 mg VGX-3100 ( 2 separate DNA plasmid respectively encode E6 E7 proteins HPV 16 HPV 18 ) 1 mg INO-9012 ( DNA plasmid encode human interleukin 12 ) ] deliver electroporation ( EP ) 25 ( twenty five ) subject HPV positive head neck cancer . The immunotherapy study follow two group subject : 1 . Subjects receive immunotherapy definitive surgery ( Cohort I ) 2 . Subjects receive immunotherapy least 2 month chemoradiation therapy ( Cohort II ) .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<criteria>1 . Signed date write Ethics Committee approve informed consent . 2 . Age ≥18 year . 3 . Histologically confirm HPVpositive ( assess p16 IHC oncogenic HPV ISH PCR ) mucosal squamous cell head neck cancer : For presurgical subject , p16 positivity must confimed prior first dose For subject postchemoradiation , HPV 16 HPV 18 positivity must confirm prior first dose . 4 . Adequate bone marrow , hepatic , renal function . ANC ( Absolute Neutrophil Count ) ≥ 1.5x109 cell/ml , platelet ≥75,000 cells/mm3 , hemoglobin ≥9.0 g/dL , concentration total serum bilirubin within 1.5 x upper limit normal ( ULN ) , AST , ALT within 2.5x institutional ULN , CPK within 2.5 x ULN . 5 . ECOG ( Eastern Cooperative Oncology Group ) performance status 01 . 1 . Anticipated concomitant immunosuppressive therapy ( exclude nonsystemic inhale , topical skin and/or eye dropcontaining corticosteroid ) . 2 . Any concurrent condition require continue use systemic steroid ( &gt; 10 mg prednisone equivalent per day ) use immunosuppressive agent . All corticosteroid must discontinue least 4 week prior Day 0 treatment . 3 . Administration vaccine within 6 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Head neck squamous cell cancer</keyword>
	<keyword>Papillomavirus</keyword>
</DOC>